Biopool's TintElize PAI-1 assay cleared by FDA:
This article was originally published in Clinica
Executive Summary
Biopool's TintElize PAI-1 assay kit has been cleared by the US FDA. The company's kit measures the level of plasminogen activator inhibitor-1 (PAI-1) in blood. High levels are thought to be an independent risk factor for thrombotic disease, including myocardial infarction. Clinical studies have shown that defective fibrinolysis is closely associated with coronary heart disease, including angina pectoris, myocardial infarction and primary cardiac arrest.